Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat

• Status: Unknown status
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effects of Chinese medicine Shensong Yangxin capsule for the chronic cardiac dysfunction complicated with ventricular premature beats.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cong-xin Huang
• Collaborators: Chinese Academy of Medical Sciences, Fuwai Hospital; Fudan University; Nanjing Medical University; Shanghai Changzheng Hospital; Third Military Medical University

Criteria

Inclusion Criteria:

• Patients with cardiac function NYHA II~III, Left ventricular ejection fraction (LVEF) 35%~50% tested by Modified Simpson, has a stable hemodynamics and no need to deliver treatment through vein

• To be treated by standard treatment of heart failure at least 3 months with a stable dosage already

• Ventricular premature beats: 720-10000 beats/24 hours

• Heart failure caused by ischemic heart disease, or dilated cardiomyopathy

Exclusion Criteria:

• Subject to be expected to alive no more than 6 months

• Subject suffered from acute coronary syndrome in last three months (Acute myocardial infarction of ST segment elevation and non ST segment elevation, unstable angina

• To be complicated with persistent atrial fibrillation, atrioventricular conduction block (II degree of Type II or III degree), or acute myocarditis

• To be complicated with ventricular fibrillation, torsion type ventricular heartbeat rate, sustained ventricular tachycardia, or non sustained ventricular tachycardia with rapid ventricular rate and hemodynamic disorders

• Sinus heart rate less than 45 beats/minutes and needs to receive the pacemaker or has received pacemaker, or with abnormal sinus node function

• The hypertension, diabetes difficult to be controlled